Comparison of glyburide and insulin in the management of gestational diabetes: A meta-analysis
Open accessThe DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: The aim of this meta-analysis was to determine the efficacy and safety of glyburide as a treatment for gestational diabetes mellitus (GDM) compared to insulin. METHODS: A meta-analysis was conducted to compare the management of gestational diabetes with glyburide and insulin. Studies fulfilling all of the following inclusion criteria were included in this meta-analysis: subjects were women with gestational diabetes requiring drug treatment; the comparison treatment included glyburide vs insulin; one or more outcomes (maternal or neonatal) should be provided in the individual study; the study design should be a randomized control trial. Exclusion criteria: non-RCT studies; non-human data. PubMed, Embase and CENTRAL databases were searched from inception until 10 October 2016. RESULTS: Ten randomized control trials involving 1194 participants met the inclusion criteria and were included. 13 primary outcomes (6 maternal, 7 neonatal) and 26 secondary outcomes (9 maternal, 17 neonatal) were detected and analyzed in this study. Glyburide significantly increased the risk of any neonatal hypoglycemia [risk ratio (RR), 1.89; 95% confidence interval (95%CI), 1.26 to 2.82; p = 0.002]. Sensitivity analysis confirmed robustness of this result [RR, 2.29; 95%CI, 1.49 to 3.54; p = 0.0002]. No differences were observed between the two groups with respect to birth weights [mean difference (MD), 79; 95%CI, -64 to 221.99; p = 0.28] and the risk of macrosomia [RR, 1.69; 95%CI, 0.57 to 5.08; p = 0.35]. CONCLUSION: For women with gestational diabetes, no differences in maternal short term outcomes were observed in those treated with glyburide or insulin. However, the incidence of neonatal hypoglycemia was higher in the glyburide group compared to the insulin group.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“recent data have raised concern about increased risk of adverse outcomes with use of glyburide compared with insulin, including increased risk of macrosomia64 and neonatal hypoglycemia.64,65”
From Gestational Diabetes Mellitus (2019) · cites this paper as [65]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Metformin versus insulin for the treatment of gestational diabetes
Rowan, J. A., Hague, W. M., Gao, W., Battin, M. R., & Moore, M. P. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707193 · Cited by 1,291
A comparison of glyburide and insulin in women with gestational diabetes mellitus
Langer, O., Conway, D. L., Berkus, M. D., Xenakis, E. M.-J., & Gonzales, O. (2000) · New England Journal of Medicine · doi:10.1056/nejm200010193431601 · Cited by 924
Gestational diabetes: the need for a common ground
Reece, E. A., Leguizamón, G., & Wiznitzer, A. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60515-8 · Cited by 589
Balsells, M., Garcia-Patterson, A., Sola, I., Roque, M., Gich, I., & Corcoy, R. (2015) · BMJ · doi:10.1136/bmj.h102 · Cited by 498
American Diabetes Association (2016) · Diabetes Care · doi:10.2337/dc16-er09 · Cited by 379
Hyperglycemia and Adverse Pregnancy Outcome (HAPO) Study
Lowe, L. P., Metzger, B. E., Dyer, A. R., Lowe, J., McCance, D. R., Lappin, T. R. J., Trimble, E. R., Coustan, D. R., Hadden, D. R., Hod, M., et al. (2012) · Diabetes Care · doi:10.2337/dc11-1687 · Cited by 367
Metformin vs insulin in the management of gestational diabetes: a meta-analysis
Gui, J., Liu, Q., & Feng, L. (2013) · PLoS ONE · doi:10.1371/journal.pone.0064585 · Cited by 222
Ijäs, H., Vääräsmäki, M., Morin-Papunen, L., Keravuo, R., Ebeling, T., Saarela, T., & Raudaskoski, T. (2011) · BJOG: An International Journal of Obstetrics & Gynaecology · doi:10.1111/j.1471-0528.2010.02763.x · Cited by 215
Treatments for gestational diabetes
Alwan, N., Tuffnell, D. J., & West, J. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003395.pub2 · Cited by 214
Camelo Castillo, W., Boggess, K., Stürmer, T., Brookhart, M. A., Benjamin, D. K., & Jonsson Funk, M. (2015) · JAMA Pediatrics · doi:10.1001/jamapediatrics.2015.74 · Cited by 177
Cited by
ACOG Practice Bulletin No. 190: Gestational Diabetes Mellitus
(2018) · Obstetrics & Gynecology · doi:10.1097/aog.0000000000002501 · Cited by 1,820
Practice Bulletin No. 183: postpartum hemorrhage
(2017) · Obstetrics & Gynecology · doi:10.1097/aog.0000000000002351 · Cited by 1,406
ACOG Practice Bulletin No. 201: Pregestational Diabetes Mellitus
(2018) · Obstetrics & Gynecology · doi:10.1097/aog.0000000000002960 · Cited by 470
Szmuilowicz, E. D., Josefson, J. L., & Metzger, B. E. (2019) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2019.05.001 · Cited by 364
15. Management of Diabetes in Pregnancy: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Echouffo-Tcheugui, J. B., Ekhlaspour, L., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s015 · Cited by 252
Guo, L., Ma, J., Tang, J., Hu, D., Zhang, W., & Zhao, X. Q. (2019) · Journal of Diabetes Research · doi:10.1155/2019/9804708 · Cited by 157
“[23] reported that no significant differences in maternal shortterm outcomes were observed between glyburide and insulin groups.”
BackgroundSénat, M.-V., Affres, H., Letourneau, A., Coustols-Valat, M., Cazaubiel, M., Legardeur, H., Jacquier, J. F., Bourcigaux, N., Simon, E., Rod, A., et al. (2018) · JAMA · doi:10.1001/jama.2018.4072 · Cited by 114
15. Management of Diabetes in Pregnancy: Standards of Care in Diabetes—2026
Bajaj, M. S., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Early, K. B., Brown, F. M., ChallaSivaKanaka, S., et al. (2025) · Diabetes Care · doi:10.2337/dc26-s015 · Cited by 180
Management of Gestational Diabetes Mellitus
Oskovi-Kaplan, Z. A., & Ozgu-Erdinc, A. S. (2020) · Advances in experimental medicine and biology · doi:10.1007/5584_2020_552 · Cited by 78
Dwivedi, D. K., & Jena, G. (2018) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-018-1540-2 · Cited by 49
Management of pregestational diabetes mellitus: a comparison of guidelines
Tsakiridis, I. G., Mamopoulos, A. M., Athanasiadis, A. P., Kourtis, A., & Dagklis, T. (2020) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.1080/14767058.2020.1719481 · Cited by 36
Wang, X., Liu, W., Chen, H., & Chen, Q. (2021) · Gynecologic and Obstetric Investigation · doi:10.1159/000515893 · Cited by 41
Oral Agents for the Treatment of Gestational Diabetes
Finneran, M. M., & Landon, M. B. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1093-2 · Cited by 36
Pharmacological Management of Gestational Diabetes Mellitus
Mukerji, G., & Feig, D. S. (2017) · Drugs · doi:10.1007/s40265-017-0807-0 · Cited by 41
Yu, D., Xu, G., Teng, X., Xu, J., Tang, L., Feng, C., Rao, J., Jin, M., & Wang, L. (2021) · BMC Endocrine Disorders · doi:10.1186/s12902-021-00865-9 · Cited by 56
Affres, H., Sénat, M., Letourneau, A., Deruelle, P., Coustols-Valat, M., Bouchghoul, H., & Bouyer, J. (2020) · Diabetes & Metabolism · doi:10.1016/j.diabet.2020.11.002 · Cited by 21
Vounzoulaki, E., & Seidu, S. (2020) · Springer eBooks · doi:10.1007/978-3-030-53370-0_35 · Cited by 17
Helal, K. F., Badr, M. S., Rafeek, M. E.-S., Elnagar, W. M., & Lashin, M. E.-B. (2020) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-019-05430-3 · Cited by 17
“[35] showed an increased risk of neonatal hypoglycemia with glyburide compared to insulin.”
BackgroundYarandi, R. B., Amiri, M., Tehrani, F. R., & Behboudi‐Gandevani, S. (2021) · Journal of Diabetes Investigation · doi:10.1111/jdi.13603 · Cited by 17
Sabbah, N., Carles, G., Demar, M., & Nacher, M. (2021) · World Journal of Diabetes · doi:10.4239/wjd.v12.i2.98 · Cited by 14
Bouchghoul, H., Alvarez, J., Verstuyft, C., Bouyer, J., & Sénat, M. (2020) · PLoS ONE · doi:10.1371/journal.pone.0232002 · Cited by 17
Chaves, C., Cunha, F., Martinho, M., Garrido, S., Silva-Vieira, M., Estevinho, C., Melo, A., Figueiredo, O., Morgado, A., Almeida, M. C., et al. (2021) · Acta Diabetologica · doi:10.1007/s00592-020-01665-8 · Cited by 12
Gomes, C. P., Futterman, I. D., Sher, O., Gluck, B., Hillier, T. A., Tehrani, F. R., Chaarani, N., Fisher, N., Berghella, V., & McLaren, R. A. (2024) · American Journal of Obstetrics & Gynecology MFM · doi:10.1016/j.ajogmf.2024.101346 · Cited by 17
Liu, K., Peng, Y., Xu, M., Kun, Y., Li, Y., Lin, C., Zhao, X., Zhu, J., Chang, Y., Lin, Z., et al. (2024) · Advanced Functional Materials · doi:10.1002/adfm.202401173 · Cited by 13
Inpatient Glycemic Management of the Pregnant Patient
Yeh, T., Yeung, M., & Curanaj, F. A. M. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1045-x · Cited by 13
Valizadeh, M., Hosseinpanah, F., Tehrani, F. R., Abdi, H., Mehran, L., Hadaegh, F., Amouzegar, A., Sarvghadi, F., Azizi, F., & Iranian Endocrine Society Task Force (2020) · Intern J Endocrinol Metab · doi:10.5812/ijem.107906 · Cited by 11
The Use of Non-insulin Agents in Gestational Diabetes: Clinical Considerations in Tailoring Therapy
Blair, R. A., Rosenberg, E. A., & Palermo, N. E. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1243-1 · Cited by 10
Treatment of Gestational Diabetes Mellitus and Offspring Early Childhood Growth
Feghali, M. N., Atlass, J., Abebe, K. Z., COMER, D. M., Catov, J. M., Caritis, S. N., Arslanian, S. A., & Scifres, C. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa742 · Cited by 10
Kelty, E. A., Tran, D. T., Atkinson, A., Preen, D. B., & Havard, A. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.0241 · Cited by 8
“23,24 Gliclazide was not associated with a significant increase in the risk of neonatal hypoglycemia compared with metformin.”
GESTATIONAL DIABETES MELLITUS: Challenges in diagnostics, management and impact
de Wit, L. (2020) · Utrecht University Repository (Utrecht University) · doi:10.33540/195 · Cited by 9
Tratamento farmacológico do diabetes na gestação
Zajdenverg, L., Dualib, P. M., Lauand, T. C. G., Reichelt, A. J., Satler, F., Façanha, C. F. S., Golbert, A., Negrato, C. A., Araújo, C. A. R., & Bertoluci, M. (2022) · Conectando Pessoas eBooks · doi:10.29327/557753.2022-13 · Cited by 51
Risk of hypoglycemia by anthropometric measurements in neonates of mothers with diabetes
Bouchghoul, H., Mitanchez, D., Letourneau, A., Bouyer, J., & Sénat, M. (2022) · European Journal of Pediatrics · doi:10.1007/s00431-022-04532-6 · Cited by 6
“A previous meta-analysis showed an increased risk of neonatal hypoglycemia in newborns from mothers treated with glyburide compared to mothers treated with insulin, but no difference in the risk of severe neonatal hypoglycemia [31].”
BackgroundMaternal diabetes negatively impacts fetal health
Corona, C. G., & Parchem, R. J. (2022) · Open Biology · doi:10.1098/rsob.220135 · Cited by 9
Huang, K., Ji, Z., Wu, Y., Huang, Y., Li, G., Zhou, S., Yang, Z., Huang, W., Yang, G., Weng, G., et al. (2020) · BMC Neurology · doi:10.1186/s12883-020-01823-z · Cited by 6
Correlates of Insulin Selection as a First-Line Pharmacological Treatment for Gestational Diabetes
Palatnik, A., Harrison, R. K., Thakkar, M. Y., Walker, R. J., & Egede, L. E. (2021) · American Journal of Perinatology · doi:10.1055/s-0041-1739266 · Cited by 5
Sun, T., Meng, F., Zang, S., Li, Y., Zhang, R., Yu, Z., Huang, X., Wang, F., Zhang, L., & Liu, J. (2021) · BMC Pregnancy and Childbirth · doi:10.1186/s12884-021-04066-z · Cited by 6
“age [18, 19] or serious neonatal outcomes [20, 21] have been reported.”
BackgroundPharmacotherapy for gestational diabetes mellitus: still insulin, or what about sulfonylureas?
Patti, A. M., Giglio, R. V., Pafili, K., Rizzo, M., & Παπάνας, Ν. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.10.60 · Cited by 6
“Secondly, this study used a neonatal criterion as the primary outcome, which was different from other works (19-21), rendering comparisons more difficult.”
ResultYu, D., Xu, G., Teng, X., Xu, J., Tang, L., Feng, C., Rao, J., Jin, M., & Wang, L. (2021) · Research Square · doi:10.21203/rs.3.rs-146509/v1 · Cited by 5
Medications for Managing Preexisting and Gestational Diabetes in Pregnancy
Rickert, M. C., Caughey, A. B., & Valent, A. M. (2023) · Obstetrics and Gynecology Clinics of North America · doi:10.1016/j.ogc.2022.10.007 · Cited by 5
Pharmacological therapy in gestational diabetes – a comparison between insulin and oral therapy
Shmuel, E., Krispin, E., Toledano, Y., Chen, R., Wiznitzer, A., & Hadar, E. (2021) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.1080/14767058.2021.1875208 · Cited by 7
“There are also studies in which no difference were shown between the groups in birthweight and macrosomia rates, including the meta-analysis presented above [18,31].”
ResultLong‐term follow‐up of children with in utero exposure to sulfonylurea medications
Rodenstein, M. S., Bianco, M. E., Ramchal, M. U., Murias, M., Silton, R. L., & Josefson, J. L. (2021) · Obesity Science & Practice · doi:10.1002/osp4.488 · Cited by 4
“Sulfonylurea exposure has been associated with increased birthweight and LGA incidence, although rigorous glucose control has been demonstrated to reduce these outcomes.(13,20,23,24) While the increased LGA incidence in this cohort may represent inferior glucose control of mothers treated with sulfonylurea, there was…”
BackgroundNeedle beats pill in gestational diabetes mellitus
Kautzky‐Willer, A., & Harreiter, J. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0050-0 · Cited by 5
Use of Antidiabetic, Antihypertensive, and Psychotropic Drugs in Pregnancy
Fasanella, D. R., Luttrell, S. E., Tejada, F. R., Ngokobi, H., & Ayuk-Tabe, M. (2018) · Side effects of drugs annual · doi:10.1016/bs.seda.2018.07.005 · Cited by 4
Antidiabéticos orais no diabetes gestacional: revisão de literatura
Araújo, P. H. D. A., Gregio, A. C. D. A. R., Scárdua, J. D. L. M., & Trindade, C. R. (2021) · Femina · doi:10.61622/0100-7254493202107 · Cited by 17
Medications for Pregnant Women With Obesity: Special Considerations
Maggio, L. (2020) · Clinical Obstetrics & Gynecology · doi:10.1097/grf.0000000000000584 · Cited by 2
Comparison of Fetal Outcome in Patients of Gestational Diabetes Treated with Met Formin and Insulin
Sajjad, F., Usman, S., Choudhry, A., Baloch, S. A., Aslam, Q. U. A., & Shahid, G. (2022) · Pakistan Armed Forces Medical Journal · doi:10.51253/pafmj.v72isuppl-2.3872 · Cited by 1
The High-Risk Obstetric Patient: Pregnancy-Induced Conditions
Curbelo, J. (2021) · Oxford University Press eBooks · doi:10.1093/med/9780190099824.003.0007 · Cited by 1
Hipoglucemiantes orales en el control metabólico de la diabetes gestacional.
Lazo-Feijoo, L. A., & Campoverde, L. H. M. (2023) · MQRInvestigar · doi:10.56048/mqr20225.7.3.2023.2454-2482
Gildin, G. S. (1983) · Hofstra law review · Cited by 2
Writers, A. M. (2018) · Drugs & Therapy Perspectives · doi:10.1007/s40267-018-0501-7
“Table 1 summarizes key clinical data from recent metaanalyses of the use of metformin [11] or glyburide [12]”
BackgroundTreatment of Gestational Diabetes
Maged, A. M. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.86988
Sun, T., Meng, F., Zang, S., Li, Y., Zhang, R., Yu, Z., Huang, X., Wang, F., Zhang, L., & Liu, J. (2021) · Research Square · doi:10.21203/rs.3.rs-330032/v1
“For the infant, there was no signi cantly difference between groups for the risk of perinatal death, being born large - for - gestational age [16,17] and serious neonatal outcomes [18,19] between women who had been treated with insulin and those treated with oral anti - diabetic pharmacological therapies.”
BackgroundChatzakis, C., Sotiriadis, A., Gerede, A., Dinas, K. D., & Nicolaides, K. H. (2022) · Springer eBooks · doi:10.1007/978-3-030-89243-2_16
Paneque, A. A. E., Ortiz, M. G. C., Maldonado, E. A. D., Matute, S. G. U., Martínez, C. E. C., & Llumiquinga, P. M. Q. (2022) · doi:10.58594/dzdk6465
Elevated Blood Sugars: Neonatal Implications of Gestational Diabetes
Sawangkum, P. S., & Ros, S. T. (2023) · NeoReviews · doi:10.1542/neo.24-6-e388
Drug-Dose-Drug-Effect Predictive Treatment Optimization for Personalized Diabetes Management
Lee, E. K., Wei, X., Wright, M. D., Baker-Witt, F., & Quarshie, A. (2025) · Lecture notes in computer science · doi:10.1007/978-3-031-81010-7_1
Yu, D.-Q., Xu, G.-X., Teng, X.-Y., Xu, J.-W., Tang, L.-F., Feng, C., Rao, J.-P., Jin, M., & Wang, L.-Q. (2021) · Figshare · doi:10.6084/m9.figshare.16800535
Yu, D.-Q., Xu, G.-X., Teng, X.-Y., Xu, J.-W., Tang, L.-F., Feng, C., Rao, J.-P., Jin, M., & Wang, L.-Q. (2021) · Figshare · doi:10.6084/m9.figshare.16800514
Yu, D.-Q., Xu, G.-X., Teng, X.-Y., Xu, J.-W., Tang, L.-F., Feng, C., Rao, J.-P., Jin, M., & Wang, L.-Q. (2021) · Figshare · doi:10.6084/m9.figshare.16800502
Yu, D.-Q., Xu, G.-X., Teng, X.-Y., Xu, J.-W., Tang, L.-F., Feng, C., Rao, J.-P., Jin, M., & Wang, L.-Q. (2021) · Figshare · doi:10.6084/m9.figshare.16800520
Yu, D.-Q., Xu, G.-X., Teng, X.-Y., Xu, J.-W., Tang, L.-F., Feng, C., Rao, J.-P., Jin, M., & Wang, L.-Q. (2021) · Figshare · doi:10.6084/m9.figshare.16800505
Yu, D.-Q., Xu, G.-X., Teng, X.-Y., Xu, J.-W., Tang, L.-F., Feng, C., Rao, J.-P., Jin, M., & Wang, L.-Q. (2021) · Figshare · doi:10.6084/m9.figshare.16800532
Yu, D.-Q., Xu, G.-X., Teng, X.-Y., Xu, J.-W., Tang, L.-F., Feng, C., Rao, J.-P., Jin, M., & Wang, L.-Q. (2021) · Figshare · doi:10.6084/m9.figshare.16800517
Yu, D.-Q., Xu, G.-X., Teng, X.-Y., Xu, J.-W., Tang, L.-F., Feng, C., Rao, J.-P., Jin, M., & Wang, L.-Q. (2021) · Figshare · doi:10.6084/m9.figshare.16800529
Yu, D.-Q., Xu, G.-X., Teng, X.-Y., Xu, J.-W., Tang, L.-F., Feng, C., Rao, J.-P., Jin, M., & Wang, L.-Q. (2021) · Figshare · doi:10.6084/m9.figshare.16800523
Yu, D.-Q., Xu, G.-X., Teng, X.-Y., Xu, J.-W., Tang, L.-F., Feng, C., Rao, J.-P., Jin, M., & Wang, L.-Q. (2021) · Figshare · doi:10.6084/m9.figshare.16800526
Yu, D.-Q., Xu, G.-X., Teng, X.-Y., Xu, J.-W., Tang, L.-F., Feng, C., Rao, J.-P., Jin, M., & Wang, L.-Q. (2021) · Figshare · doi:10.6084/m9.figshare.16800538
Yu, D.-Q., Xu, G.-X., Teng, X.-Y., Xu, J.-W., Tang, L.-F., Feng, C., Rao, J.-P., Jin, M., & Wang, L.-Q. (2021) · Figshare · doi:10.6084/m9.figshare.16800508
Yu, D.-Q., Xu, G.-X., Teng, X.-Y., Xu, J.-W., Tang, L.-F., Feng, C., Rao, J.-P., Jin, M., & Wang, L.-Q. (2021) · Figshare · doi:10.6084/m9.figshare.16800499
Yu, D.-Q., Xu, G.-X., Teng, X.-Y., Xu, J.-W., Tang, L.-F., Feng, C., Rao, J.-P., Jin, M., & Wang, L.-Q. (2021) · Figshare · doi:10.6084/m9.figshare.16800496
Yu, D.-Q., Xu, G.-X., Teng, X.-Y., Xu, J.-W., Tang, L.-F., Feng, C., Rao, J.-P., Jin, M., & Wang, L.-Q. (2021) · Figshare · doi:10.6084/m9.figshare.16800511
Topatan, E., Topatan, A. S., Kilic, M., Halici, B., & Çadırcı, E. (2026) · Journal of obstetrics and gynaecology research · doi:10.1111/jog.70256 · Cited by 1
“Glyburide treatment is associated with a higher risk of neonatal hypoglycemia and macrosomia [38–41].”
Bouchghoul, H. (2021) · theses.fr (ABES) · doi:10.70675/148e6519z0c6dz4cbfza432z81cde39ecdbc
Metadata
- Authors
- Song, R., Chen, L., Chen, Y., Si, X., Liu, Y., Liu, Y., Irwin, D. M., & Feng, W.
- Affiliations
- Peking University People's Hospital (CN)
- University of Toronto (CA)
- Corresponding author
- Irwin, David M.
- Feng, Wanyu
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2017-08-03
- Volume
- 12
- Issue
- 8
- Pages
- e0182488
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC5542468
- OpenAlex
- W2744038916
- Cited by
- 73
- References
- 43
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 3 · 2023: 3 · 2022: 6 · 2021: 29 · 2020: 11 · 2019: 5 · 2018: 10 · 2017: 2
- FWCI
- 1.30
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Topics
- Health Sciences › Medicine › Obstetrics and Gynecology › Gestational Diabetes Research and Management
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pregnancy and Medication Impact
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- gestational diabetes mellitus, glibenclamide, insulin therapy, neonatal hypoglycemia, macrosomia, birth weight, maternal outcomes, neonatal outcomes, antidiabetic drug comparison
- MeSH terms
- Adult, Birth Weight, Female, Glyburide, Humans, Hypoglycemia, Hypoglycemic Agents, Infant, Newborn, Infant, Newborn, Diseases, Insulin, Pregnancy, Research Design, Incidence, Randomized Controlled Trials as Topic, Diabetes, Gestational, Treatment Outcome, Disease Management
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.